1
|
Hollmann A, Cardoso NP, Espeche JC, Maffía PC. Review of antiviral peptides for use against zoonotic and selected non-zoonotic viruses. Peptides 2021; 142:170570. [PMID: 34000327 PMCID: PMC8120785 DOI: 10.1016/j.peptides.2021.170570] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/28/2020] [Revised: 04/23/2021] [Accepted: 05/04/2021] [Indexed: 12/15/2022]
Abstract
Viruses remain one of the leading causes of animal and human disease. Some animal viral infections spread sporadically to human populations, posing a serious health risk. Particularly the emerging viral zoonotic diseases such as the novel, zoonotic coronavirus represent an actual challenge for the scientific and medical community. Besides human health risks, some animal viral infections, although still not zoonotic, represent important economic loses to the livestock industry. Viral infections pose a genuine concern for which there has been an increasing interest for new antiviral molecules. Among these novel compounds, antiviral peptides have been proposed as promising therapeutic options, not only for the growing body of evidence showing hopeful results but also due to the many adverse effects of chemical-based drugs. Here we review the current progress, key targets and considerations for the development of antiviral peptides (AVPs). The review summarizes the state of the art of the AVPs tested in zoonotic (coronaviruses, Rift Valley fever viruses, Eastern Equine Encephalitis Virus, Dengue and Junín virus) and also non-zoonotic farm animal viruses (avian and cattle viruses). Their molecular target, amino acid sequence and mechanism of action are summarized and reviewed. Antiviral peptides are currently on the cutting edge since they have been reported to display anti-coronavirus activity. Particularly, the review will discuss the specific mode of action of AVPs that specifically inhibit the fusion of viral and host-cell membranes for SARS-CoV-2, showing in detail some important features of the fusion inhibiting peptides that target the spike protein of these risky viruses.
Collapse
Affiliation(s)
- Axel Hollmann
- Laboratorio de Compuestos Bioactivos, Centro de Investigaciones en Biofísica Aplicada y Alimentos (CIBAAL), CONICET, Universidad Nacional de Santiago del Estero, RN 9, Km 1125, 4206, Santiago del Estero, Argentina; Laboratorio de Microbiología Molecular, Instituto de Microbiología Básica y Aplicada, Universidad Nacional de Quilmes, Roque Sáenz Peña 352, B1876BXD, Bernal, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas, CONICET, Buenos Aires, Argentina
| | - Nancy P Cardoso
- Instituto de Virología e Innovaciones Tecnológicas, IVIT - Instituto Nacional de Tecnología Agropecuaria (INTA), Hurlingham, Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas, CONICET, Buenos Aires, Argentina
| | - Juan C Espeche
- Laboratorio de Compuestos Bioactivos, Centro de Investigaciones en Biofísica Aplicada y Alimentos (CIBAAL), CONICET, Universidad Nacional de Santiago del Estero, RN 9, Km 1125, 4206, Santiago del Estero, Argentina
| | - Paulo C Maffía
- Instituto de Biotecnología, Universidad Nacional de Hurlingham, Av. Vergara 2222, Villa Tesei, Hurlingham, B1688GEZ, Buenos Aires, Argentina; Consejo Nacional de Investigaciones Científicas y Técnicas, CONICET, Buenos Aires, Argentina.
| |
Collapse
|